Table 3.

Effects of MAP kinase and PI3 kinase inhibitors and a PDGF receptor-blocking antibody on proliferation of human dermal fibroblasts in response to Gd³⁺-phosphate.

Treatment groups	Number of cells ×10−4
Control	5.0 ± 1.1
Gd3+-phosphate	6.2 ± 1.5*
+ U0126 (10 μM)	4.6 ± 1.4**
Control	5.8 ± 0.6
Gd3+-phosphate	7.0 ± 0.9*
+LY294002 (25 μM)	5.3 ± 1.8**
Control	5.1 ± 0.5
Gd3+-phosphate	6.6 ± 0.7*
+ anti-PDGFr antibody (10 μg/ml)	6.7 ± 0.7

Values shown are means and standard deviations based on four separate experiments with duplicate or triplicate samples per data point. Statistical significance of the data was assessed by ANOVA, followed by paired-group comparisons.

^*indicates statistically significant increase compared to negative control at p<0.05 level.

^**indicates statistically significant decrease compared to Gd³⁺ -phosphate alone.